Understanding transmitted HIV resistance through the experience in the USA

International Journal of Infectious Diseases

Volumn 13, Issue 5, 2009, Pages 552-559

  Taiwo, Babafemi ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

HIV; Transmitted resistance

Indexed keywords

ANTIVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CELL COMPARTMENTALIZATION; COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DISEASE COURSE; DISEASE TRANSMISSION; GENITAL SYSTEM; GENOTYPE; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MINORITY GROUP; MULTIDRUG RESISTANCE; NONHUMAN; RESERVOIR; REVIEW; UNITED STATES; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; UNITED STATES;

EID: 65349154421     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2008.10.008     Document Type: Review

References (102)

1. Richman D.D., Morton S.C., Wrin T., Hellmann N., Berry S., Shapiro M.F., et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 18 (2004) 1393-1401
2. Smith D., Moini N., Pesano R., Cachay E., Aiem H., Lie Y., et al. Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection. Clin Infect Dis 44 (2007) 456-458
3. Conlon C.P., Klenerman P., Edwards A., Larder B.A., and Phillips R.E. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis 169 (1994) 411-415
4. Quigg M., Rebus S., France A.J., McMenamin J., Darby G., and Leigh Brown A.J. Mutations associated with zidovudine resistance in HIV-1 among recent seroconvertors. AIDS 11 (1997) 835-836
5. Conway B., Montessori V., Rouleau D., Montaner J.S., O'Shaughnessy M.V., Fransen S., et al. Primary lamivudine resistance in acute/early human immunodeficiency virus infection. Clin Infect Dis 28 (1999) 910-911
6. de Ronde A., Schuurman R., Goudsmit J., van den Hoek A., and Boucher C. First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, the Netherlands. AIDS 10 (1996) 231-232
7. Veenstra J., Schuurman R., Cornelissen M., van't Wout A.B., Boucher C.A., Schuitemaker H., et al. Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus. Clin Infect Dis 21 (1995) 556-560
8. Johnson V.A., Petropoulos C.J., Woods C.R., Hazelwood J.D., Parkin N.T., Hamilton C.D., et al. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. J Infect Dis 183 (2001) 1688-1693
9. Kamkamidze G., Sullivan T., and Charbonneau T. Occurrence of HIV-1 reverse transcriptase gene mutation at codon 215 in HIV-infected infants. J Clin Virol 22 (2001) 143-148
10. Bauer G., Colgrove R.C., Larussa P.S., Pitt J., and Welles S.L. Antiretroviral resistance in HIV transmitting mothers and their infants. AIDS 20 (2006) 1707-1712
11. Larder B.A., Darby G., and Richman D.D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243 (1989) 1731-1734
12. Erice A., Mayers D.L., Strike D.G., Sannerud K.J., McCutchan F.E., Henry K., et al. Brief report: transmitted infection with zidovudine-resistant human immunodeficiency virus type-1. N Engl J Med 328 (1993) 1163-1165
13. Peuchant O., Capdepont S., Ragnaud J.M., Aurillac-Lavignolle V., Thiébaut R., Fleury H., et al. Primary resistance to enfuvirtide (T20) in recently HIV-1 infected, antiretroviral-naive patients from the ANRS Aquitaine Cohort. Antivir Ther 12 (2007) 559-562
14. Boden D., Hurley A., Zhang L., Cao Y., Guo Y., Jones E., et al. HIV drug resistance in newly infected individuals. JAMA 282 (1999) 1135-1141
15. Little S.J., Daar E.S., D'Aquila R.T., Keiser P.H., Connick E., Whitcomb J.M., et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 282 (1999) 1142-1149
16. Weidle P.J., Ganea C.E., Irwin K.L., Pieniazek D., McGowan J.P., Olivo N., et al. Presence of human immunodeficiency virus (HIV) type 1, group M, non-B subtypes, Bronx, New York: a sentinel site for monitoring HIV genetic diversity in the United States. J Infect Dis 181 (2000) 470-475
17. Parker M.M., Gordon D., Reilly A., Horowitz H.W., Waters M., Bennett R., et al. Prevalence of drug-resistant and nonsubtype B HIV strains in antiretroviral-naïve. HIV-infected individuals in New York State. AIDS Patient Care STDS 21 (2007) 644-652
18. Weinstock H.S., Zaidi I., Heneine W., Bennett D., Garcia-Lerma J.G., Douglas Jr. J.M., et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 189 (2004) 2174-2180
19. Ross L., Lim M.L., Liao Q., Wine B., Rodriguez A.E., Weinberg W., et al. Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities. HIV Clin Trials 8 (2007) 1-8
20. Little S.J., Holte S., Routy J.P., Daar E.S., Markowitz M., Collier A.C., et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347 (2002) 385-394
21. Weinstock H., Respess R., Heneine W., Petropoulos C.J., Hellmann N.S., Luo C.C., et al. Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998. J Infect Dis 182 (2000) 330-333
22. Grant R.M., Hecht F.M., Warmerdam M., Liu L., Liegler T., Petropoulos C.J., et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288 (2002) 181-188
23. Karchava M., Pulver W., Smith L., Philpott S., Sullivan T.J., Wethers J., et al. Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State. J Acquir Immune Defic Syndr 42 (2006) 614-619
24. Eshleman S.H., Husnik M., Hudelson S., Donnell D., Huang Y., Huang W., et al. Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection. AIDS 21 (2007) 1165-1174
25. Simon V., Vanderhoeven J., Hurley A., Ramratnam B., Louie M., Dawson K., et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 16 (2002) 1511-1519
26. Shet A., Berry L., Mohri H., Mehandru S., Chung C., Kim A., et al. Tracking the prevalence of transmitted antiretroviral drug resistant HIV-1. A decade of experience. J Acquir Immune Defic Syndr 41 (2006) 439-446
27. Ross L.L., Dix L., Wine B., Vavro C., Horton J., and Pappa K.A. Changes in regional prevalence, clade, and epidemiology of HIV-1 drug resistance mutations and clade among antiviral therapy-naive patients in the United States from 2000 to 2007. Antivir Ther 13 Suppl (2008) A160
28. Shafer R.W., Rhee S., Pillay D., Miller V., Sandstrom P., Schapiro J.M., et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 21 (2007) 215-223
29. Bennett D, Kiuchi M, Rhee SY, Pillay D, Miller V, van de Vijver D, et al. The World Health Organization 2008 list of mutations for surveillance of transmitted drug resistant HIV strains. Abstract 38. 3rd International Workshop on HIV Transmission: Principles of Intervention. July 31-August 2, 2008, Mexico City.
30. Turner D., and Wainberg M. HIV transmission and transmitted drug resistance. AIDS Rev 8 (2006) 17-23
31. de Mendoza C., Rodríguez C., Eiros J., Colomina J., Garcia F., Leiva P., et al. Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV. Clin Infect Dis 41 (2005) 227-232
32. Duwe S., Brunn M., Altmann D., Hamouda O., Schmidt B., Walter H., et al. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy naive patients of the German seroconverter study. J Acquir Immune Defic Syndr 26 (2001) 266-273
33. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in transmitted infections in the United Kingdom. BMJ 322 (2001) 1087-1088
34. Routy J.P., Brenner B., Machouf N., Thomas R., Trottier B., et al. Temporal trend in non-nucleoside reverse transcriptase inhibitor (NNRTI) transmitted drug resistance: relationship with chronically infected potential transmitter population. Antivir Ther 13 Suppl 3 (2008) A161
35. Brenner B.G., Roger M., Routy J.P., Moisi D., Wainberg M.A., and the Quebec Primary HIV Infection (PHI) Study Group. Impact of clustering on the transmission of HIV-1 variants harbouring drug resistance. Antivir Ther 13 Suppl 3 (2008) A163
36. Truong H.M., Klausner J.D., Hecht F.M., and Grant T.M. Reduced levels of transmitted resistance to NRTIs in San Francisco is discernable using two independent sentinel populations. Antivir Ther 11 (2006) S115
37. Hu Z., Giguel F., Hatano H., Reid P., Lu J., and Kuritzkes D.R. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J Virol 80 (2006) 7020-7027
38. Turner D., Brenner B., Routy J.P., Moisi D., Rosberger Z., Roger M., et al. Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr 37 (2004) 1627-1631
39. Colgrove R.C., Pitt J., Chung P.H., Welles S.L., and Japour A.J. Selective vertical transmission of HIV-1 antiretroviral resistance mutations. AIDS 12 (1998) 2281-2288
40. Martinez-Picado J., Savara A.V., Sutton L., and D'Aquila R.T. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 73 (1999) 3744-3752
41. Yerly S., Jost S., Telenti A., Flepp M., Kaiser L., Chave J.P., et al. Infrequent transmission of HIV-1 drug-resistant variants. Antivir Ther 9 (2004) 375-384
42. Leigh Brown A.J., Frost S.D., Mathews W.C., Dawson K., Hellmann N.S., Daar E.S., et al. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 187 (2003) 683-686
43. de Mendoza C., Rodriguez C., Corral A., del Romero J., Gallego O., and Soriano V. Evidence for differences in the sexual transmission efficiency of HIV strains with distinct drug resistance genotypes. Clin Infect Dis 39 (2004) 1231-1238
44. Wensing A.M., van de Vijver D.A., Angarano G., Asjö B., Balotta C., Boeri E., et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 192 (2005) 958-966
45. Kashuba A.D., Dyer J.R., Kramer L.M., Raasch R.H., Eron J.J., and Cohen M.S. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother 43 (1999) 1817-1826
46. Lafeuillade A., Solas C., Halfon P., Chadapaud S., Hittinger G., and Lacarelle B. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. HIV Clin Trials 3 (2002) 27-35
47. Solas C., Lafeuillade A., Halfon P., Chadapaud S., Hittinger G., and Lacarelle B. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 47 (2003) 238-243
48. Venturi G., Catucci M., Romano L., Corsi P., Leoncini F., Valensin P.E., et al. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. J Infect Dis 181 (2000) 740-745
49. Ghosn J., Viard J.P., Katlama C., de Almeida M., Tubiana R., Letourneur F., et al. Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV infected men. AIDS 18 (2004) 447-457
50. Chakraborty H., Helms R.W., Sen P.K., and Cohen M.S. Estimating correlation by using a general linear mixed model: evaluation of the relationship between the concentration of HIV-1 RNA in blood and semen. Stat Med 22 (2003) 1457-1464
51. Liuzzi G., Chirianni A., Zaccarelli M., Zinzi D., Esposito V., Guadagnino V., et al. Differences between semen and plasma of nucleoside reverse transcriptase resistance mutations in HIV-infected patients, using a rapid assay. In Vivo 18 (2004) 509-512
52. Tirado G., Jove G., Kumar R., Noel R.J., Reyes E., Sepulveda G., et al. Compartmentalization of drug resistance-associated mutations in a treatment-naive HIV-infected female. AIDS Res Hum Retroviruses 20 (2004) 684-686
53. Zhang H., Dornadula G., Beumont M., Livornese Jr. L., Van Uitert B., Henning K., et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 339 (1998) 1803-1809
54. Delobel P., Sandres-Sauné K., Cazabat M., L'Faqihi F.E., Aquilina C., Obadia M., et al. Persistence of distinct HIV-1 populations in blood monocytes and naive and memory CD4 T cells during prolonged suppressive HAART. AIDS 19 (2005) 1739-1750
55. Smith D.M., Wong J.K., Shao H., Hightower G.K., Mai S.H., Moreno J.M., et al. Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission. J Infect Dis 196 (2007) 356-360
56. Wei X., Decker J., Wang S., Hui H., Kappes J.C., Wu X., et al. Antibody neutralization and escape by HIV-1. Nature 422 (2003) 307-312
57. Cheng-Mayer C., Brown A., Harouse J., Luciw P., and Mayer A. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. J Virol 73 (1999) 5294-5300
58. Ghosn J., Pellegrin I., Goujard C., Deveau C., Viard J.P., Galimand J., et al. HIV-1 resistant strains acquired at the time of transmitted infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 20 (2006) 159-170
59. Barbour J.D., Hecht F.M., Wrin T., Liegler T.J., Ramstead C.A., Busch M.P., et al. Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 18 (2004) 1653-1660
60. Yerly S., Junier T., Boffi E., Gunthard H.F., Zdobnov E., Hirschel B., et al. Drug resistance in newly HIV diagnosed individuals: transmission rate, clusters and persistence. Antivir Ther 13 Suppl 3 (2008) A167
61. Deeks S.G., Wrin T., Liegler T., Hoh R., Hayden M., Barbour J.D., et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 344 (2001) 472-480
62. Garcia-Lerma J.G., Nidtha S., Blumoff K., Weinstock H., and Heneine W. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Natl Acad Sci U S A 98 (2001) 13907-13912
63. Baraboutis I.G., Papastamopoulos V., Georgiou O., and Skoutelis A.T. Revertant multiresistant HIV in chronically infected drug naïve patients: when baseline resistance testing is not enough. Int J STD AIDS 18 (2007) 722
64. Gandhi R.T., Wurcel A., Rosenberg E.S., Johnston M.N., Hellmann N., Bates M., et al. Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis 37 (2003) 1693-1698
65. Descamps D., Calvez V., Izopet J., Buffet-Janvresse C., Schmuck A., Colson P., et al. Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide study. AIDS 15 (2001) 1777-1782
66. Imrie A., Carr A., Duncombe C., Finlayson R., Vizzard J., Law M., et al. Primary infection with zidovudine-resistant human immunodeficiency virus type 1 does not adversely affect outcome at 1 year. Sydney Primary HIV Infection Study Group. J Infect Dis 174 (1996) 195-198
67. Little SJ, Grant RM, Daar ES, Markowitz M, Hecht FM, Johnson V, et al. Transmitted NNRTI drug resistance is associated with higher steady state viral load measures in untreated subjects with primary HIV infection. Poster 49. 12th International HIV Drug Resistance Workshop. June 2004, Tenerife.
68. Bezemer D., Jurriaans S., Prins M., van der Hoek L., Prins J.M., de Wolf F., et al. Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. AIDS 18 (2004) 1571-1577
69. de Mendoza C, Ortiz M, Pérez-Hoyos S, Corral A, García-Saínz A, del Amo J, et al. Impact of transmission of drug-resistant HIV strains on viral load, CD4 counts and CD4 decline in recent seroconverters. Poster 81. 12th International Workshop on HIV Drug Resistance. June 2003, Los Cabos.
70. Chan K.C., Galli R.A., Montaner J.S., and Harrigan P.R. Prolonged retention of drug resistance mutations and rapid disease progression in the absence of therapy after primary HIV infection. AIDS 17 (2003) 1256-1258
71. Markowitz M., and Boden D. Multidrug-resistant, dual-tropic HIV-1 and rapid progression. Lancet 365 (2005) 1924
72. Wensing AM, van de Vijver DA, Vercauteren J, Albert J, Bratt G, Clumeck N, et al. Comparative disease progression observed in newly diagnosed patients infected with drug resistant and susceptible virus: no signs for increased virulence. 3rd International AIDS Society Meeting. July 2005, Rio de Janeiro.
73. Poggensee G., Kucherer C., Werning J., Somogyi S., Bieniek B., Dupke S., et al. Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study. HIV Med 8 (2007) 511-519
74. Pillay D., Bhaskaran K., Jurriaans S., Prins M., Masquelier B., Dabis F., et al. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS 20 (2006) 21-28
75. Borroto-Esoda K., Waters J.M., Bae A.S., Harris J.L., Hinkle J.E., Quinn J.B., et al. Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. AIDS Res Hum Retroviruses 23 (2007) 988-995
76. Violin M., Cozzi-Lepri A., Velleca R., Vincenti A., D'Elia S., Chiodo F., et al. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS 18 (2004) 227-235
77. Kuritzkes D.R., Lalama C.M., Ribaudo H.J., Marcial M., Meyer III W.A., Shikuma C., et al. Preexisting resistance to non-nucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 197 (2008) 867-870
78. Oette M., Kaiser R., Daumer M., Petch R., Fatkenheuer G., Carls H., et al. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 41 (2006) 573-581
79. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. DHHS; 2008. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf (accessed December 2008).
80. Hirsch M.S., Brun-Vezinet F., Clotet B., Conway B., Kuritzkes D.R., D'Aquila R.T., et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an international AIDS Society-USA Panel. Clin Infect Dis 37 (2003) 113-128
81. Sax P.E., Islam R., Walensky R.P., Losina E., Weinstein M.C., Goldie S.J., et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 41 (2005) 1316-1323
82. Vicenti I., Razzolini F., Saladini F., Romano L., and Zazzi M. Use of peripheral blood DNA for genotype antiretroviral resistance testing in drug-naive HIV-infected subjects. Clin Infect Dis 44 (2007) 1657-1661
83. Johnson J.A., Li J.F., Wei X., Lipscomb J., Irlbeck D., Craig C., et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 5 7 (2008) e158
84. Hare C.B., Mellors J., Krambrink A., Su Z., Skiest D., Margolis D.M., et al. Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis 47 3 (2008) 421-424
85. Flys T.S., Donnell D., Mwatha A., Nakabiito C., Musoke P., Mmiro F., et al. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis 195 5 (2007) 711-715
86. Palmer S., Maldarelli F., Wiegand A., Bernstein B., Hanna G.J., Brun S.C., et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 105 10 (2008) 3879-3884
87. Paredes R, Lalama C, Ribaudo H, Schackman, B; Shikuma, C, Meyer W, et al. Presence of minor populations of Y181C mutants detected by allele-specific PCR (ASPCR) and risk of efavirenz failure in treatment-naïve patients: results of an ACTG A5095 case-cohort study. Abstract 83. Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections. February 3-6, 2008, Boston, Massachusetts.
88. Bennet D.E., Myatt M., Bertagnolio S., Sutherland D., and Gilks C. Recommendations for surveillance of transmitted resistance in countries scaling up antiretroviral treatment. Antivir Ther 13 Suppl 2 (2008) 25-36
89. Blower S., Brodine E., Kahn J., and McFarland W. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS 19 (2005) 1-14
90. Aghokeng A.F., Vergne L., Atem-Tambe A., Tongo M., Peyou M.N., Butel C., et al. Evaluation of transmitted HIV drug resistance using the WHO HIV drug resistance threshold survey model in four Central African countries. Antivir Ther 13 Suppl 3 (2008) A149
91. Pillay V., Ledwaba J., Hunt G., Rakgotho M., Singh B., Makubalo L., et al. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province. South Africa in 2002 and 2004. Antivir Ther 13 Suppl 2 (2008) 101-107
92. Maphalala G., Okello V., Mndzebele S., Gwebu P., Mulima N., Dlamini S., et al. Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006. Antivir Ther 13 Suppl 2 (2008) 95-100
93. Abegaz W.E., Grossman Z., Wolday D., Ram D., Kaplan J., Sibide K., et al. Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia. Antivir Ther 13 Suppl 2 (2008) 89-94
94. Kamoto K., Aberle-Grasse J., and Malawi HIV Drug Resistance Task Force. Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antivir Ther 13 Suppl 2 (2008) 83-87
95. Somi G.R., Kibuka T., Diallo K., Tuhuma T., Bennett D.E., Yang C., et al. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antivir Ther 13 Suppl 2 (2008) 77-82
96. Ndembi N., Lyagoba F., Nanteza B., Kushemererwa G., Serwanga J., Katongole-Mbidde E., et al. Transmitted antiretroviral drug resistance surveillance among newly HIV type 1-diagnosed women attending an antenatal clinic in Entebbe, Uganda. AIDS Res Hum Retroviruses 24 (2008) 889-895
97. Brenner B.G., Roger M., Routy J.P., Moisi D., Ntemgwa M., Matte C., et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 195 (2007) 951-959
98. Pernas M., Casado C., Fuentes R., Pérez-Elías M.J., and López-Galíndez C. A dual superinfection and recombination within HIV-1 subtype B 12 years after primoinfection. J Acquir Immune Defic Syndr 42 (2006) 12-18
99. Quinn T.C., Wawer M.J., Sewankambo N., Serwadda D., Li C., Wabwire-Mangen F., et al., for the Rakai Project Study Group. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 342 (2000) 921-929
100. Tovanabutra S., Robison V., Wongtrakul J., Sennum S., Suriyanon V., Kingkeow D., et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr 29 (2002) 275-283
101. Barreiro P., del Romero J., Leal M., Hernando V., Asencio R., de Mendoza C., et al. Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy. J Acquir Immune Defic Syndr 43 (2006) 324-326
102. Hammer S.M., Eron Jr. J.J., Reiss P., Schooley R.T., Thompson M.A., Walmsley S., et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300 5 (2008) 555-570